Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk

Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
Record ID 32018001153
Authors' objectives: Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD). The assessment aimed to provide valid data on clinical effectiveness and safety of the WCD. Comparators were chosen based on CE mark indications, recommendations from relevant published clinical guidelines and according to the EUnetHTA guidelines. Furthermore, the project intended to elicit patients’ views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.
Project Status: Completed
Year Published: 2016
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
MeSH Terms
  • Death, Sudden, Cardiac
  • Defibrillators, Implantable
  • Electric Countershock
  • Wearable Electronic Devices
  • Arrhythmias, Cardiac
  • Defibrillators
Organisation Name: European Network for Health Technology Assessment
Contact Email: eunethta@zinl.nl
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.